Answers are grounded in this paper and cite their sources.
Dr. Lieberman or an immediate family member serves as a paid consultant to DePuy; has received research or institutional support from Amgen and Arthrex; and serves as a board member, owner, officer, or committee member of the American Academy of Orthopaedic Surgeons (AAOS) and American Association of Hip and Knee Surgeons and as an AAOS representative to the Surgical Care Improvement Project (SCIP). Dr. Lieberman is Director, New England Musculoskeletal Institute, and Professor and Chairman, Department of Orthopaedic Surgery, University of Connecticut Health Center, Farmington, CT, and Deputy Editor, Hip and Knee, Journal of the American Academy of Orthopaedic Surgeons, Rosemont, IL. http://dx.doi.org/10.5435/JAAOS-20–06–333
No takes yet. Share an insight, caveat, or question.
Jay R. Lieberman (2012) conducted an editorial in Venous Thromboembolism. Venous Thromboembolic Prophylaxis was evaluated. This editorial discusses guidelines for venous thromboembolic prophylaxis but contains no primary clinical data or findings in the provided text.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: